Liver-directed Therapies in Liver Metastases from Neuroendocrine Tumors of the Gastrointestinal Tract

Overview

Journal Target Oncol

Specialty Oncology

Date 2012 Jun 19

PMID 22707276

Citations 19

Authors

Magaly Zappa

Mohamed Abdel-Rehim

Olivia Hentic

Marie-Pierre Vullierme

Philippe Ruszniewski

Valerie Vilgrain

Affiliations

Soon will be listed here.

Abstract

Presence of liver metastases in neuroendocrine tumors is a major factor altering both quality of life and prognosis. Surgery is recognized as the sole curative treatment. When it is not possible, radiological directed therapies are crucial, particularly in liver metastases from the small bowel. Thermal ablative therapies as radiofrequency ablation and microwave are alternative treatments alone or in combination with surgery. Hepatic artery embolization or chemoembolization, as radioembolization, has been shown to have good clinical, biochemical, and morphological responses when liver burden does not permit ablative therapies. However, technical issues are multiple and there is no randomized study to compare their efficacy. The choice of management depends on liver burden and metastases pattern, but also on origin of the primary tumor, tumor differentiation, and tumor proliferative activity. These patients should benefit of a multidisciplinary management to limit morbidity and mortality.

Citing Articles

Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors.

Fields B, Ayabe R, Seo Y, Maxwell J, Halperin D Curr Oncol Rep. 2024; 26(11):1530-1542.

PMID: 39466478 PMC: 11776107. DOI: 10.1007/s11912-024-01610-w.

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

Eads J, Halfdanarson T, Asmis T, Bellizzi A, Bergsland E, Dasari A Endocr Relat Cancer. 2023; 30(8).

PMID: 37184955 PMC: 10388681. DOI: 10.1530/ERC-22-0206.

Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors.

Marchese U, Gaillard M, Pellat A, Tzedakis S, Ali E, Dohan A Cancers (Basel). 2022; 14(2).

PMID: 35053593 PMC: 8773540. DOI: 10.3390/cancers14020433.

Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience.

Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M Cancers (Basel). 2021; 13(21).

PMID: 34771531 PMC: 8582443. DOI: 10.3390/cancers13215366.

Neuroendocrine Carcinomas of the Digestive Tract: What Is New?.

Pellat A, Cottereau A, Terris B, Coriat R Cancers (Basel). 2021; 13(15).

PMID: 34359666 PMC: 8345167. DOI: 10.3390/cancers13153766.

References

Eriksson B, Larsson E, Skogseid B, Lofberg A, Lorelius L, Oberg K . Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998; 83(11):2293-301. View

Kim Y, Ajani J, Carrasco C, Dumas P, Richli W, Lawrence D . Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999; 17(7):474-8. DOI: 10.3109/07357909909032856. View

Bilchik A, Sarantou T, Foshag L, Giuliano A, Ramming K . Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery. 1998; 122(6):1040-7; discussion 1047-8. DOI: 10.1016/s0039-6060(97)90207-5. View

Kress O, Wagner H, Wied M, Klose K, Arnold R, Alfke H . Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis. Digestion. 2003; 68(2-3):94-101. DOI: 10.1159/000074522. View

Gupta S, Yao J, Ahrar K, Wallace M, Morello F, Madoff D . Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003; 9(4):261-7. DOI: 10.1097/00130404-200307000-00008. View

Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V . Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2011; 56(3):609-17. DOI: 10.1016/j.jhep.2011.09.012. View

Pitt S, Knuth J, Keily J, McDermott J, Weber S, Chen H . Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg. 2008; 12(11):1951-60. PMC: 3342849. DOI: 10.1007/s11605-008-0640-6. View

Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L . Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005; 242(2):158-71. PMC: 1357720. DOI: 10.1097/01.sla.0000171032.99149.fe. View

Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S . Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993; 71(8):2624-30. DOI: 10.1002/1097-0142(19930415)71:8<2624::aid-cncr2820710830>3.0.co;2-b. View

10.

Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S . Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol. 2003; 180(5):1379-84. DOI: 10.2214/ajr.180.5.1801379. View

11.

Elias D, Lefevre J, Duvillard P, Goere D, Dromain C, Dumont F . Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think. Ann Surg. 2009; 251(2):307-10. DOI: 10.1097/SLA.0b013e3181bdf8cf. View

12.

Hoffmann R, Paprottka P, Jakobs T, Trumm C, Reiser M . Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdom Imaging. 2011; 36(6):671-6. DOI: 10.1007/s00261-011-9753-6. View

13.

Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y . Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000; 190(4):432-45. DOI: 10.1016/s1072-7515(00)00222-2. View

14.

de Baere T, Roche A, Amenabar J, Lagrange C, Ducreux M, Rougier P . Liver abscess formation after local treatment of liver tumors. Hepatology. 1996; 23(6):1436-40. DOI: 10.1002/hep.510230620. View

15.

Seifert J, Cozzi P, Morris D . Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol. 1998; 14(2):175-83. DOI: 10.1002/(sici)1098-2388(199803)14:2<175::aid-ssu10>3.0.co;2-2. View

16.

Cao C, Yan T, Bester L, Liauw W, Morris D . Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010; 97(4):537-43. DOI: 10.1002/bjs.6931. View

17.

Kim W, Clark T, Baum R, Soulen M . Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol. 2001; 12(8):965-8. DOI: 10.1016/s1051-0443(07)61577-2. View

18.

Rhee T, Lewandowski R, Liu D, Mulcahy M, Takahashi G, Hansen P . 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008; 247(6):1029-35. DOI: 10.1097/SLA.0b013e3181728a45. View

19.

Maire F, Lombard-Bohas C, OToole D, Vullierme M, Rebours V, Couvelard A . Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012; 96(4):294-300. DOI: 10.1159/000336941. View

20.

Osborne D, Zervos E, Strosberg J, Strosberg J, Boe B, Malafa M . Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006; 13(4):572-81. DOI: 10.1245/ASO.2006.03.071. View